McMaster
University – February 12, 2020 -- A new group of antibiotics with a unique
approach to attacking bacteria has been discovered, making it a promising
clinical candidate in the fight against antimicrobial resistance.
The
newly-found corbomycin and the lesser-known complestatin have a
never-before-seen way to kill bacteria, which is achieved by blocking the
function of the bacterial cell wall. The discovery comes from a family of
antibiotics called glycopeptides that are produced by soil bacteria.
The
researchers also demonstrated in mice that these new antibiotics can block
infections caused by the drug resistant Staphylococcus aureus which is a
group of bacteria that can cause many serious infections.
The
findings were published in Nature today.
"Bacteria
have a wall around the outside of their cells that gives them shape and is a
source of strength," said study first author Beth Culp, a PhD candidate in
biochemistry and biomedical sciences at McMaster.
"Antibiotics
like penicillin kill bacteria by preventing building of the wall, but the
antibiotics that we found actually work by doing the opposite -- they prevent
the wall from being broken down. This is critical for cell to divide.
"In
order for a cell to grow, it has to divide and expand. If you completely block
the breakdown of the wall, it is like it is trapped in a prison, and can't
expand or grow."
Looking
at the family tree of known members of the glycopeptides, researchers studied
the genes of those lacking known resistance mechanisms, with the idea they
might be an antibiotic demonstrating a different way to attack bacteria.
"We
hypothesized that if the genes that made these antibiotics were different,
maybe the way they killed the bacteria was also different," said Culp.
The
group confirmed that the bacterial wall was the site of action of these new
antibiotics using cell imaging techniques in collaboration with Yves Brun and
his team from the Université de Montréal.
Culp
said: "This approach can be applied to other antibiotics and help us
discover new ones with different mechanisms of action. We found one completely
new antibiotic in this study, but since then, we've found a few others in the
same family that have this same new mechanism."
The
team is led by professor Gerry Wright of the David Braley Centre for Antibiotic
Discovery within the Michael G. DeGroote Institute for Infectious Disease
Research at McMaster.
The
research was funded by the Canadian Institutes of Health Research and the
Ontario Research
Fund.
Story
Source:
Materials provided by McMaster University. Original
written by Tina Depko. Note: Content may be edited for style and length.
https://www.sciencedaily.com/releases/2020/02/200212131523.htm